Journey is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The Journey team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey was formed in 2014 and is a subsidiary of Fortress Biotech, Inc. Journey’s core purpose is to positively impact people’s lives and well-being by providing effective solutions for treating skin conditions, healing wounds and supporting healthy skin.
Company profile
Ticker
DERM
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
JG Pharma Inc. ...
IRS number
471879539
DERM stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Mar 24
8-K
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
21 Mar 24
8-K
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
2 Jan 24
S-8
Registration of securities for employees
15 Dec 23
8-K
Departure of Directors or Certain Officers
8 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
7 Nov 23
8-K
Other Events
26 Sep 23
8-K
Other Events
19 Sep 23
8-K
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations
6 Sep 23
Transcripts
DERM
Earnings call transcript
2023 Q3
7 Nov 23
DERM
Earnings call transcript
2022 Q4
29 Mar 23
DERM
Earnings call transcript
2022 Q3
12 Nov 22
DERM
Earnings call transcript
2022 Q2
10 Aug 22
DERM
Earnings call transcript
2022 Q1
15 May 22
DERM
Earnings call transcript
2019 Q3
6 Nov 19
DERM
Earnings call transcript
2019 Q2
8 Aug 19
DERM
Earnings call transcript
2019 Q1
8 May 19
DERM
Earnings call transcript
2018 Q4
27 Feb 19
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.75 mm | 24.75 mm | 24.75 mm | 24.75 mm | 24.75 mm | 24.75 mm |
Cash burn (monthly) | (no burn) | 845.17 k | (no burn) | 990.25 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | 5.79 mm | n/a | 6.79 mm | n/a | n/a |
Cash remaining | n/a | 18.95 mm | n/a | 17.96 mm | n/a | n/a |
Runway (months of cash) | n/a | 22.4 | n/a | 18.1 | n/a | n/a |
Institutional ownership, Q3 2023
87.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 5 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 4.77 bn |
Total shares | 12.15 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FBIO Fortress Biotech | 10.01 mm | $82.09 mm |
Tang Capital Management | 576.10 k | $1.58 bn |
RILY B. Riley Financial | 429.60 k | $1.18 bn |
Nantahala Capital Management | 348.66 k | $955.34 mm |
Perkins Capital Management | 224.30 k | $615.00 k |
AFG American Financial | 180.00 k | $493.00 k |
Neuberger Berman | 110.55 k | $302.92 mm |
Vanguard | 72.67 k | $199.11 mm |
Geode Capital Management | 69.51 k | $190.52 mm |
Brighton Jones | 23.02 k | $63.08 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Rosenwald Lindsay A MD | Common Stock, $0.0001 par value | Buy | Acquire P | No | No | 3.04 | 10,000 | 30.40 k | 144,245 |
22 Mar 24 | Claude Maraoui | Common Stock, $0.0001 par value | Buy | Acquire P | No | No | 3.479 | 10,000 | 34.79 k | 2,163,430 |
22 Mar 24 | Justin Adam Smith | Common Stock, $0.0001 par value | Buy | Acquire P | No | No | 3.47 | 30,000 | 104.10 k | 134,717 |
22 Mar 24 | Rosenwald Lindsay A MD | Common Stock, $0.0001 par value | Buy | Acquire P | No | No | 3.4 | 20,000 | 68.00 k | 134,245 |
28 Nov 23 | Jeffrey Paley | Common Stock, par value $0.0001 per share | Sell | Dispose S | No | No | 5.22 | 1,745 | 9.11 k | 70,727 |
News
Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying
28 Mar 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
26 Mar 24
Recap: Journey Medical Q4 Earnings
21 Mar 24
Journey Medical Q4 2023 Adj EPS $0.03 Beats $(0.08) Estimate, Sales $15.257M Beat $15.061M Estimate
21 Mar 24
Press releases
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
21 Mar 24
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
15 Mar 24
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
13 Mar 24
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
11 Mar 24